FDA Determines Regulatory Review Period for SENSIPAR Patent Extension

Summary

The Food and Drug Administration has officially confirmed the regulatory review period for SENSIPAR, a human drug product, in accordance with federal regulations, following a patent extension application submitted to the US Department of Commerce.